A single drug now does what used to require separate treatments for kidneys and heart. On January 28, 2025, the FDA approved Ozempic (semaglutide) as the first GLP-1 receptor agonist to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The approval came after the landmark FLOW trial was stopped early because the drug was working so well — delivering a 24 percent reduction in kidney disease progression and kidney-related or cardiovascular mortality compared to placebo across 3,533 patients in 28 countries. For readers of this site, the connection between kidney health, heart health, and brain health matters more than most people realize.
Chronic kidney disease and cardiovascular disease share overlapping risk factors with dementia, including hypertension, diabetes, and chronic inflammation. When a medication can simultaneously protect the kidneys and the heart, it may also be reducing the vascular damage that contributes to cognitive decline over time. This article examines the new kidney disease drugs that have cardiologists paying attention, the clinical evidence behind them, the emerging combination therapies, and what all of this means for patients managing multiple chronic conditions. Beyond semaglutide, the combination of finerenone and empagliflozin has shown striking results, and updated 2026 guidelines from the American Diabetes Association now position these drugs as cornerstone therapies. We will walk through each of these developments, their limitations, and what patients and caregivers should realistically expect.
Table of Contents
- Why Does a New Kidney Disease Drug Have Cardiologists So Excited?
- How Semaglutide Performed in the FLOW Trial — And Where It Falls Short
- Combination Therapy — Finerenone and Empagliflozin Together
- What Patients and Caregivers Should Discuss With Their Doctors
- The Kidney-Heart-Brain Connection and Why Dementia Caregivers Should Pay Attention
- SGLT2 Inhibitors and GLP-1 Receptor Agonists Used Together
- Where Kidney and Heart Therapies Are Headed
- Conclusion
- Frequently Asked Questions
Why Does a New Kidney Disease Drug Have Cardiologists So Excited?
The short answer is that kidneys and the heart are deeply intertwined — so much so that nephrologists and cardiologists have coined the term “cardiorenal syndrome” to describe how failure in one organ accelerates damage in the other. When the FLOW trial demonstrated that semaglutide not only slowed kidney decline but also reduced cardiovascular events and all-cause death, it confirmed what researchers had hoped: targeting the metabolic pathways connecting these organs could yield benefits across both systems simultaneously. The trial enrolled patients at roughly 400 sites, and secondary endpoints showed slower decline in estimated glomerular filtration rate (eGFR), the standard measure of kidney function, alongside fewer heart attacks and strokes. Compare this to older approaches. For decades, the standard of care for CKD in diabetic patients was blood pressure management with ACE inhibitors or ARBs — drugs that helped the kidneys but did little for cardiovascular outcomes beyond blood pressure control.
SGLT2 inhibitors like empagliflozin changed that equation a few years ago by showing dual kidney and heart benefits. Now semaglutide adds a third pillar, working through a completely different mechanism as a GLP-1 receptor agonist. The practical result is that physicians have more tools, and patients with both CKD and heart risk finally have treatments designed with both organs in mind rather than one at the expense of the other. One important caveat: the FLOW trial studied patients with type 2 diabetes and CKD specifically. Patients with kidney disease from other causes, such as polycystic kidney disease or lupus nephritis, were not included. Extrapolating the benefits to non-diabetic kidney disease requires further research, though trials are underway.
How Semaglutide Performed in the FLOW Trial — And Where It Falls Short
The numbers from the FLOW trial are worth examining closely. Over a median follow-up of 3.4 years, 331 patients in the semaglutide group experienced a primary endpoint event (kidney disease progression, kidney failure, kidney-related death, or cardiovascular death) compared to 410 in the placebo group. That 24 percent relative risk reduction led the independent data monitoring committee to stop the trial early — a decision that only happens when the evidence of benefit is considered overwhelming and it would be unethical to continue giving some patients a placebo. However, stopping a trial early can also inflate the apparent effect size. This is a known statistical phenomenon, and some researchers have cautioned that the real-world benefit may be somewhat more modest than what the headline number suggests.
Additionally, semaglutide comes with gastrointestinal side effects — nausea, vomiting, and diarrhea — that cause a meaningful number of patients to discontinue treatment. For elderly patients, particularly those already dealing with reduced appetite or frailty, these side effects can be more than a nuisance. Weight loss from semaglutide, which is a benefit for many, can actually be harmful in frail older adults who cannot afford to lose muscle mass. The 2025 oral semaglutide SOUL trial, which evaluated 9,650 patients, found a 14 percent reduction in major adverse cardiovascular events versus placebo. While that number is lower than the FLOW trial’s kidney-specific outcomes, it reinforces the cardiovascular signal and provides data on an oral formulation that may be easier for some patients than weekly injections.
Combination Therapy — Finerenone and Empagliflozin Together
One of the most promising developments is the idea that combining drugs from different classes may produce additive benefits. The CONFIDENCE trial, published in the new England Journal of Medicine, tested exactly this by randomly assigning 800 patients across 143 sites in 14 countries to receive finerenone alone, empagliflozin alone, or the combination. At day 180, the combination reduced the urinary albumin-to-creatinine ratio — a key marker of kidney damage — by 29 percent more than finerenone alone and 32 percent more than empagliflozin alone. Perhaps the most striking finding was that 70 percent of patients on the combination therapy achieved the American Diabetes Association’s recommended target of greater than 30 percent UACR reduction, compared to only 52 percent on either drug alone. Kerendia (finerenone) on its own is already proven to reduce heart attack risk, cardiovascular death, and heart failure hospitalization while slowing CKD progression in type 2 diabetes.
Adding empagliflozin, an SGLT2 inhibitor, appears to push outcomes meaningfully further. For a concrete example, consider a 68-year-old patient with type 2 diabetes, stage 3 CKD, and a history of heart failure. Previously, their cardiologist and nephrologist might have been working from different playbooks. Now, a combination regimen addresses both specialists’ concerns in a coordinated way. That said, combining medications also means monitoring for more side effects, including the risk of hyperkalemia with finerenone — elevated potassium levels that can be dangerous, particularly when kidney function is already compromised.
What Patients and Caregivers Should Discuss With Their Doctors
The practical question for patients is not which drug is “best” in isolation but which combination makes sense for their particular profile of risks. A patient with type 2 diabetes, early-stage CKD, and significant cardiovascular risk might benefit most from adding semaglutide to their existing regimen. A patient already on an SGLT2 inhibitor who still has elevated albumin levels might benefit from adding finerenone. The 2026 ADA Standards of Care now emphasize SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists like finerenone as cornerstone therapies for CKD risk management with cardiovascular co-benefits. The tradeoff between injectable and oral medications deserves discussion as well.
Semaglutide is available as a weekly injection (Ozempic) and as a daily oral tablet (Rybelsus), though the CKD-specific FDA approval currently applies to the injectable form based on the FLOW trial data. For older adults who may have difficulty with self-injection, or for caregivers managing complex medication schedules, the oral option may be more practical — but patients should understand that the strongest kidney-specific evidence is with the injectable version. Cost is another reality. These medications are expensive, and insurance coverage varies widely. A month’s supply of Ozempic can exceed one thousand dollars without insurance, and prior authorization requirements can delay treatment. Patients should ask their doctors about assistance programs and whether generic alternatives exist for any part of their regimen.
The Kidney-Heart-Brain Connection and Why Dementia Caregivers Should Pay Attention
Chronic kidney disease is increasingly recognized as an independent risk factor for cognitive decline and dementia. Impaired kidney function leads to the accumulation of uremic toxins, chronic inflammation, and vascular damage — all of which affect the brain. Studies have shown that patients with CKD have higher rates of both vascular dementia and Alzheimer’s disease compared to age-matched controls with normal kidney function. When cardiovascular disease is layered on top, the risk compounds further. This is why drugs that protect both the kidneys and the heart have implications beyond their primary indications.
By slowing kidney decline and reducing cardiovascular events, medications like semaglutide and finerenone may indirectly reduce the cerebrovascular damage that contributes to cognitive impairment. However, no clinical trial has yet demonstrated a direct reduction in dementia risk from these specific drugs, and it would be premature to take them solely for brain protection. The connection is plausible and supported by mechanistic evidence, but definitive proof requires dedicated studies. For caregivers managing a loved one with both diabetes and early cognitive changes, the key takeaway is this: aggressive management of kidney and cardiovascular risk is not just about preventing dialysis or heart attacks. It is about preserving the vascular health that the brain depends on. Bringing up these newer medications at the next nephrology or cardiology appointment is a reasonable step.
SGLT2 Inhibitors and GLP-1 Receptor Agonists Used Together
Separate from the finerenone combination data, research on pairing SGLT2 inhibitors with GLP-1 receptor agonists has also shown impressive results. When SGLT2 inhibitors were added to GLP-1 receptor agonist therapy, CKD progression risk dropped by 33 percent, and the annual loss of kidney function slowed by almost 60 percent. These are substantial numbers that suggest the two drug classes work through complementary mechanisms — GLP-1 agonists addressing metabolic and inflammatory pathways while SGLT2 inhibitors reduce intraglomerular pressure and glucose reabsorption in the kidneys.
A practical limitation is that using both drug classes simultaneously increases the complexity and cost of treatment. Patients on both medications require closer monitoring of blood sugar levels to avoid hypoglycemia, particularly if they are also taking insulin or sulfonylureas. Dose adjustments are common, and the gastrointestinal side effects of GLP-1 agonists can be compounded in patients who are sensitive to medication changes.
Where Kidney and Heart Therapies Are Headed
The direction of treatment is clearly toward multi-target, combination-based approaches. The 2026 ADA guidelines reflect this shift by placing SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRAs at the center of CKD management rather than as add-ons. Ongoing trials are investigating whether these benefits extend to patients without diabetes, whether earlier intervention produces even better outcomes, and whether brain-specific endpoints like cognitive decline can be meaningfully measured in these populations.
For patients and caregivers, the practical outlook is cautiously encouraging. A year after the CKD approval, semaglutide is already being described as transformative for diabetes-related kidney and heart care. The combination data from the CONFIDENCE trial and the SGLT2-plus-GLP-1 studies suggest that physicians will have increasingly powerful regimens at their disposal. The challenge will be ensuring that these treatments reach the patients who need them most, including older adults and those in underserved communities where CKD often goes undiagnosed until it is advanced.
Conclusion
The approval of semaglutide for chronic kidney disease marked a turning point — the first time a GLP-1 receptor agonist was shown to protect both kidneys and the cardiovascular system in a single indication. Combined with the CONFIDENCE trial’s demonstration that finerenone and empagliflozin together outperform either drug alone, and the broader data on SGLT2-plus-GLP-1 combinations, the treatment landscape for CKD with cardiovascular risk has fundamentally changed. The 2026 ADA guidelines now reflect this new reality by positioning these drug classes as foundational rather than supplementary.
For readers concerned about brain health, the message is nuanced but important. Protecting the kidneys and heart protects the vasculature that the brain relies on. While no one should take these medications specifically to prevent dementia, ensuring that kidney disease and cardiovascular risk are managed with the best available therapies is one of the most concrete steps a patient or caregiver can take to support long-term cognitive health. Talk with your medical team about whether these newer options belong in your treatment plan, and do not assume that older regimens are still sufficient just because they were once the standard of care.
Frequently Asked Questions
Is Ozempic now FDA-approved specifically for kidney disease?
Yes. On January 28, 2025, the FDA approved Ozempic (semaglutide) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This is separate from its approvals for blood sugar control and weight management.
Can these kidney drugs help prevent dementia?
There is no direct clinical evidence yet that semaglutide or finerenone prevents dementia. However, by protecting kidney function and reducing cardiovascular events, these drugs may help preserve the vascular health that supports brain function. Dedicated studies on cognitive outcomes are still needed.
What are the main side effects of semaglutide for CKD patients?
The most common side effects are gastrointestinal — nausea, vomiting, and diarrhea. For older or frail patients, the associated weight loss can also be a concern if it leads to muscle wasting. Patients should discuss these risks with their doctor, especially if they are already underweight or have poor appetite.
Does the finerenone and empagliflozin combination require special monitoring?
Yes. Finerenone can raise potassium levels, which is a particular concern in patients with reduced kidney function. Regular blood tests to monitor potassium and kidney function are essential when using this combination. Patients should not start or adjust these medications without medical supervision.
Are these drugs only for people with diabetes?
The current FDA approval for semaglutide in CKD and the CONFIDENCE trial data on finerenone plus empagliflozin are specific to patients with type 2 diabetes. Research is ongoing to determine whether similar benefits extend to patients with kidney disease from other causes.
How much do these medications cost?
Without insurance, semaglutide can cost over one thousand dollars per month. Finerenone and empagliflozin also carry significant costs. Coverage varies by insurance plan, and prior authorization is often required. Patient assistance programs from manufacturers may help reduce out-of-pocket expenses.
